Literature DB >> 1355264

Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines.

J J Enyeart1, B A Biagi, B Mlinar.   

Abstract

We have used the whole-cell version of the patch-clamp technique to analyze the inhibition of Ca2+ currents by antipsychotic agents in neural crest-derived rat and human thyroid C cell lines. Diphenylbutylpiperidine (DPBP) antipsychotics, including penfluridol and fluspirilene, potently and preferentially block T-type Ca2+ current in the rat medullary thyroid carcinoma 6-23 (clone 6) cell line. When step depolarizations were applied at 0.1 Hz from a holding potential of -80 mV, with 10 mM Ca2+ as the charge carrier, the DPBP penfluridol inhibited T-type current with an IC50 of 224 nM. High voltage-activated L and N currents were less potently blocked. At a concentration of 500 nM, penfluridol inhibited 78.0 +/- 2.3% (n = 29) of inactivating T-type Ca2+ current, whereas the sustained high voltage-activated current was reduced by 25.6 +/- 3.5% (n = 28). Block of T-type current by penfluridol was enhanced by depolarizing test pulses applied at frequencies above 0.03 Hz. The use-dependent component of block was largely reversed by pulse-free periods at -80 mV. T-type Ca2+ channels in the human TT C cell line were blocked by penfluridol, and the potency was enhanced by reduction of extracellular Ca2+. Non-DPBP antipsychotics, including haloperidol, clozapine, and thioridazine, also blocked T-type channels, but these were 20-100 times less potent than the DPBPs. These results identify the DPBPs as a new class of organic Ca2+ channel antagonists, which are distinctive in their ability to preferentially block T-type channels. These agents will be useful in defining the function of T channels in various excitable cells. Their potent block of T-type Ca2+ channels, which would be enhanced in rapidly firing cells, suggests that this action may be relevant to the therapeutic or toxic effects of these drugs when used in clinical pharmacology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355264

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

Review 1.  Low-voltage-activated ("T-Type") calcium channels in review.

Authors:  Anne Marie R Yunker; Maureen W McEnery
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 2.  Modulation and pharmacology of low voltage-activated ("T-Type") calcium channels.

Authors:  Anne Marie R Yunker
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 3.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine.

Authors:  Claudia Rangel-Barajas; Ana María Estrada-Sánchez; Scott J Barton; Robert R Luedtke; George V Rebec
Journal:  Neuropharmacology       Date:  2016-11-02       Impact factor: 5.250

5.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

6.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Authors:  Shunmoogum A Patten; Dina Aggad; Jose Martinez; Elsa Tremblay; Janet Petrillo; Gary Ab Armstrong; Alexandre La Fontaine; Claudia Maios; Meijiang Liao; Sorana Ciura; Xiao-Yan Wen; Victor Rafuse; Justin Ichida; Lorne Zinman; Jean-Pierre Julien; Edor Kabashi; Richard Robitaille; Lawrence Korngut; J Alexander Parker; Pierre Drapeau
Journal:  JCI Insight       Date:  2017-11-16

7.  Differential inhibition of T-type calcium channels by neuroleptics.

Authors:  Celia M Santi; Francisco S Cayabyab; Kathy G Sutton; John E McRory; Janette Mezeyova; Kevin S Hamming; David Parker; Anthony Stea; Terrance P Snutch
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

Review 8.  Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Authors:  Thomas Pietschmann
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

Review 9.  Molecular pharmacology of high voltage-activated calcium channels.

Authors:  Clinton J Doering; Gerald W Zamponi
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

10.  Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells.

Authors:  K Nakazawa; K Ito; S Koizumi; Y Ohno; K Inoue
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.